Table 3.

Comparison of TLR2 and IFNL3 multilocus genotypes frequencies of HCV-related patients with liver (n = 405), HCV-related lymphoproliferative diseases (n = 238) and blood donors (n = 94).

IFNL3	TLR2	BD	CHC	Cirrhosis	HCC	Hepatic diseases	Hepatic vs. BD OR (95%CI), p†	BD	MC	NHL	Lympho-proliferative	Lympho-proliferative vs. hepatic OR (95%CI), p†
C	Ins	0.58	0.47	0.45	0.45	0.45		0.58	0.54	0.53	0.53
T	Ins	0.29	0.36	0.39	0.35	0.37	1.68 (1.1-2.7) p = 0.028	0.29	0.30	0.35	0.32	0.72 (0.6–0.9) p = 0.014
C	Del	0.10	0.11	0.10	0.13	0.11		0.10	0.12	0.10	0.11
T	Del	0.03	0.07	0.07	0.07	0.07		0.03	0.05	0.02	0.04	0.43 (0.2–0.9) p = 0.016

BD, blood donors (controls); CHC, chronic hepatitis C; HCC, hepatocellular carcinoma; MC, mixed cryoglobulinemia; NHL, non-Hodgkin lymphoma; ^†only significant results were reported. OR, odds ratio; 95% CI, 95% confidence interval.